Reporting owner · CIK 0001235598
Frates James M
Visual SEC Form 4 history across 2 companies, 7 transactions and 6 filings.
CFOChief Financial OfficerAmylyx Pharmaceuticals, Inc.
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 24
$0
Jan 25
$0
Mar 25
$0
Jan 26
−$37K
Feb 26
−$52.1K
Aug 26
$0
Transaction texture
Ownership and ticket size
Average P/S size$44.5K
Median P/S size$44.5K
Direct7
Indirect0
Aug 18, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at Amylyx Pharmaceuticals, Inc. on Feb 02, 2026 valued at $52,097.
Review SEC filingLatest buy
No open-market insider purchase is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| AMLX | FRATES JAMES M | CFO | grant | 22.8k | $0 | A | −12.5% | 08/21 | 08/18 | |
| AMLX | FRATES JAMES M | CFO | sale | 3.55k | -$5.20M | S | +18.4% | 02/04 | 02/02 | |
| AMLX | FRATES JAMES M | CFO | sale | 3.32k | -$3.69M | S | — | 01/08 | 01/06 | |
| AMLX | FRATES JAMES M | CFO | grant | 102k | $0 | A | — | 03/11/2025 | 03/06/2025 | |
| AMLX | FRATES JAMES M | CFO | grant | 68.4k | $0 | A | — | 03/11/2025 | 03/06/2025 | |
| SAGE | FRATES JAMES M | DIR | grant | 19.1k | $0 | A | — | 01/06/2025 | 01/03/2025 | |
| SAGE | FRATES JAMES M | DIR | grant | 4.92k | $0 | A | — | 01/04/2024 | 01/03/2024 |
Frates James M Insider Activity FAQ
SEC Form 4 context
Who is Frates James M?
Frates James M is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001235598.
Which companies has Frates James M reported transactions for?
Amylyx Pharmaceuticals, Inc., Sage Therapeutics, Inc.
When was Frates James M's latest insider buy?
No open-market insider purchase is available for this period.
When was Frates James M's latest insider sale?
sale at Amylyx Pharmaceuticals, Inc. on Feb 02, 2026 valued at $52,097.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.